[796967-16-3] Linifanib AKSci SYN1002
 
 
Loading Please Wait...
  SYN1002    
Linifanib
, >95% (HPLC)
 
ABT-869
AL-39324
RG3635




IDENTITY
CAS Number:[796967-16-3]
MDL Number:MFCD11840918
MF:C21H18FN5O
MW:375.41
SPECIFICATIONS & PROPERTIES
Purity:>95% (HPLC)
Available Spectra:LCMS, HPLC
Physical Form:Off white to light brown powder
Long-Term Storage:Store long-term at -20°C

BIOLOGICAL INFO
Solubility:DMSO 75mg/mL, Ethanol 5mg/mL
Application(s):PDGFR

REVIEW

 Linifanib (A 741439; A-741439; A741439; ABT-869; ABT869; RG3635) is an orally active multi-targeted receptor tyrosine kinase inhibitor for the treatment of various cancers. The compound is designed to inhibit vascular endothelial growth factor and platelet-derived growth factor receptors and is a multitargeted tyrosine kinase receptor inhibitor that suppresses FLT3 signaling. It is in phase III development for liver cancer and phase II development for non-small cell lung cancer, breast cancer, and colorectal cancer in the US, the EU and other areas of the world. (PMID:20698720); Recent research also indicates that Linifanib inhibits proliferation and induces apoptosis in AML patient cells via reduction of AKT and GSK3beta phosphorylation and maybe influential in AML therapy. (PMID:21471285)

GHS

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501


Current as of June 25, 2017


Download SDS


PubChem